Pfizer announced that its investigational 25-valent pneumococcal conjugate vaccine (25vPnC) showed up to 15-fold higher antibody responses compared to Prevnar 20 in a Phase 2 infant study. Based on these positive results, the company has initiated a Phase 3 pediatric program.
- The new pediatric program aims to achieve 90% serotype coverage in children under 5 years of age.
- The vaccine candidate was well-tolerated with no safety concerns identified during the study.
- Pfizer also plans to advance a fifth-generation 35-valent adult vaccine candidate to reinforce its franchise leadership.